このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

一部の進行性固形腫瘍患者を対象とした、SOCS1 および Regnase-1 をコードする遺伝子を不活化するように操作された自己腫瘍浸潤リンパ球である KSQ-004EX の第 1/2 相試験

2026年10月29日 更新者:M.D. Anderson Cancer Center

Phase 1 is to find the recommended dose of KSQ-004EX to give to participants with advanced solid tumors.

Phase 2 is to learn if KSQ-004EX at the recommended dose found in Phase1 can help to control advanced solid tumors.

The safety and effects of KSQ-004EX will also be studied in both phases.

調査の概要

詳細な説明

Phase 1: Dose Escalation

Primary Objective:

  • To evaluate the safety and tolerability of KSQ-004EX in adult participants with advanced solid tumors (melanoma, NSCLC, HNSCC, CRC, pancreatic cancer, and cervical cancer) Secondary Objectives
  • Determine expansion dose
  • Assess the safety and tolerability of KSQ-004EX in participants with advanced solid tumors (melanoma, NSCLC, HNSCC, CRC, pancreatic cancer, and cervical cancer)
  • Evaluate preliminary anti-tumor activity of KSQ-004EX in participants with advanced solid tumors
  • Evaluate the feasibility of the manufacturing process

Phase 2: Expansion Primary Objective

  • To assess the anti-tumor activity of KSQ-004EX in participants with advanced malignant solid tumors Secondary Objectives
  • Assess the safety and tolerability of KSQ-004EX in participants with advanced solid tumors (melanoma, NSCLC, HNSCC, CRC, pancreatic cancer, and cervical cancer)
  • Evaluate anti-tumor activity of KSQ-004EX in participants with advanced malignant solid tumors
  • Evaluate overall survival (OS)
  • Evaluate the feasibility of the manufacturing process

研究の種類

介入

入学 (推定)

141

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • MD Anderson Cancer Center
        • コンタクト:
        • 主任研究者:
          • Rodabe N Amaria, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Diagnosed with one of the following tumor types:

    1. Unresectable, incurable and/or metastatic histologically and/or cytologically confirmed cutaneous, acral, or unknown primary melanoma (Stage IIIC or Stage IV) that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting, one of which includes treatment with anti-PD-1/PD-L1 inhibitor alone or in combination with anti-cytotoxic T lymphocyte associated protein 4 (anti-CTLA-4) inhibitor or in combination with anti-LAG-3 antibody.

      Note: Up to 5 mucosal patients can be treated in the melanoma expansion cohort only.

    2. Histologically and/or cytologically confirmed primary diagnosis of NSCLC which has progressed on at least 1 line and no more than 4 lines of prior therapy in the advanced/metastatic setting, including platinum-based chemotherapy and checkpoint inhibitor therapy (either given in combination or sequentially).

    i. Participants with tumors that have known actionable molecular alteration such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS-1, B-Raf proto-oncogene (BRAF), rearranged during transfection (RET), MET and Kirsten Rat Sarcoma Virus (KRAS) must have progressed on standard directed molecular therapy in addition to platinum-based chemotherapy.

    Note, the following do not count towards a line of prior therapy:

    • Any therapy/regimen discontinued due to intolerance/tolerability issues

    • Retreatment with the same class or previous class of treatment alone or in combination c. Locally advanced recurrent and/or metastatic histologically and/or cytologically confirmed HNSCC that has been previously treated with at least 1 and no more than 4 lines of prior therapy in the advanced/metastatic setting.

      i. Participants must have received a platinum-containing chemotherapy regimen for the treatment of primary tumor in locally advanced, or metastatic setting d. Advanced, metastatic histologically and/or cytologically confirmed colorectal adenocarcinoma that has progressed following at least 1 and no more than 3 lines of prior therapy. Participants with dMMR/MSI-H or KRASG12C BRAF V600E mutation must have progressed on standard directed therapy.

      e. Locally advanced, recurrent, or metastatic histologically and/or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting.

      f. Recurrent, metastatic, or persistent histologically and/or cytologically confirmed squamous cell carcinoma (SCC), adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting.

  2. Resectable lesion for KSQ-004EX manufacturing (tumor ≥ 1.5 cm2 or at least 5 core needle biopsies)

  3. At least one measurable lesion per RECIST v1.1 (Eisenhauer 2009) following tumor resection for KSQ-004EX manufacturing Note: Lesions in previously irradiated areas should not be selected as a target lesion unless radiation treatment was ≥ 3 months prior, and there has been demonstrated disease progression in the lesion

  4. Age ≥ 18 years of age

  5. Life expectancy of ≥ 12 weeks

  6. Recovered to ≤ Grade 1 or Baseline toxicity (except alopecia, neuropathy, and endocrinopathies from prior immunotherapy) from prior therapy (per the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE])

  7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

  8. Adequate bone marrow function defined as:

    1. Absolute neutrophil count (ANC) of ≥ 1 × 109/L
    2. Platelet count of ≥ 100.0 × 109/L
    3. Hemoglobin of ≥ 9.0 g/dL
  9. Adequate renal function defined as calculated creatinine clearance (Cockcroft-Gault) ≥ 40 mL/min

  10. Adequate hepatic function defined as:

    1. Total bilirubin ≤ 2.0 × upper limit of normal (ULN) unless associated with Gilbert's syndrome
    2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN (or ≤ 5 × ULN in patients with liver metastases)
  11. Washout period from prior anticancer therapy(ies) of a minimum duration (excluding bridging therapy per concomitant medication, see Section 6.11) is required prior to the first study treatment (i.e., start of LDC therapy) as detailed below:

    1. Targeted therapy: prior targeted therapy with an EGFR, ALK, receptor tyrosine kinase, or other-directed agent (eg, erlotinib, afatinib, osimertinib, crizotinib, ceritinib), is allowed provided the washout is a minimum of 7 days or 5 half-lives, whichever is longer prior to start of therapy (LDC)
    2. Monoclonal antibodies with a washout of at least 21 days or 5 half-lives or whichever is longer
    3. Chemotherapy: adjuvant, neoadjuvant or definitive chemotherapy/chemoradiation is allowed provided the washout is a minimum of 21 days or 5 half-lives, whichever is shorter
    4. Radiation therapy: prior external beam radiation is allowed provided a minimum of 14 days have elapsed between the last dose of radiation and first study treatment (LDC)
    5. Surgery: previous surgical procedure(s) is permitted provided that wound healing has occurred and at least 14 days have elapsed (for major operative procedures) prior to the first study treatment (LDC)
  12. Female participants who are women of childbearing potential (WOCP), (defined as physiologically and anatomically capable of becoming pregnant), confirmed of a negative pregnancy test and agreement to the use of a highly effective contraceptive method or at least 2 effective methods at the same time during study treatment period and for up to 3 months after study treatment (KSQ-004EX infusion). Male participants must be willing to use effective barrier contraception (ie, condoms) during the study treatment period and for up 3 months after study treatment (KSQ-004EX infusion)

    a. This includes all female participants, between the onset of menses (as early as 8 years of age) and 55 years unless the participant presents with an applicable exclusionary factor which may be one of the following: i. Postmenopausal (no menses in greater than or equal to 12 consecutive months).

    ii. History of hysterectomy or bilateral salpingo-oophorectomy. iii. Ovarian failure (follicle stimulating hormone and estradiol in menopausal range, who have received whole pelvic radiation therapy).

    iv. History of bilateral tubal ligation or another surgical sterilization procedure.

    b. Approved methods of birth control are as follows: hormonal contraception (ie, birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device (IUD), tubal Ligation or hysterectomy, subject/partner post-vasectomy, implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

  13. Ability to understand and the willingness to sign a written informed consent document

  14. Signed and dated Institutional Review Board (IRB) approved informed consent form (ICF) before any protocol-directed Screening procedures are performed

Exclusion Criteria:

  1. Prior organ allograft or prior cell therapy that included LDC or myeloablative chemotherapy regimen

  2. Known hypersensitivity to any component of KSQ-004EX or excipient including dimethyl sulfoxide, human serum albumin, LDC regimen (cyclophosphamide or fludarabine) or IL-2 (as applicable)

  3. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, Grade ≥ 2 colitis or Crohn's disease], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis], rheumatoid arthritis, etc.]). The following are exceptions to this criterion:

    1. Participants with vitiligo or alopecia
    2. Participants with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
    3. Any chronic skin condition that does not require systemic therapy
    4. Participants with celiac disease controlled by diet alone
  4. Hypersensitivity to antibiotics of the aminoglycoside group (eg, streptomycin, gentamicin) or penicillin

  5. Active, uncontrolled concurrent infection requiring IV antibiotics present at Screening

  6. Uveal and/or ocular melanoma

  7. Large cell neuroendocrine NSCLC (defined as pathology with >10% neuroendocrine components)

  8. Symptomatic and/or untreated brain metastases (of any size or number) including active leptomeningeal or parenchymal metastases.

    Note: Participants with definitively treated brain metastases may be considered for enrollment if stable (defined as stable for 1-month post-central nervous system directed therapy) after discussion with the drug provider (KSQ)

  9. Participants with ascites

  10. Women who are pregnant or nursing

  11. Seropositive for human immunodeficiency virus (HIV) 1 or 2 or acquired immunodeficiency syndrome, or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) Note: Participants with positive HCV antibody may be eligible if HCV ribonucleic acid (RNA) is undetectable on a quantitative HCV RNA assay, following discussion with the drug provider (KSQ)

  12. Any form of primary immunodeficiency (eg, Severe Combined Immunodeficiency Disease)

  13. Any known clinically significant or concurrent acute liver disease, including viral hepatitis

  14. Previous solid organ or hematopoietic cell transplant

  15. Need for treatment with steroids at stable doses (> 10 mg/day prednisone or equivalent)

    1. Topical, ophthalmic, or inhaled steroid medications are allowed
    2. Systemic steroid (>10 mg/day) use is not allowed for 14 days prior to enrollment
    3. Systemic steroids < 10 mg/day are permitted if for supplemental endocrine only Note: steroids can be administered for IV contrast allergy
  16. Live or unattenuated vaccine < 28 days prior to first dose of LDC regimen

  17. History of stroke, transient ischemic attack, unstable angina, or myocardial infarction, within 3 months prior to first dose of study treatment

  18. Symptomatic congestive heart failure according to New York Heart Association (NYHA) classification, Class III or IV (per NYHA Classification), unstable angina pectoris, clinically significant cardia arrhythmia, or left ventricular ejection fraction < 45%

  19. Prolongation of QT/QTc interval (QTc interval > 480 msec) using the Frederica method of QTc analysis

  20. Unable to walk a distance of 80% predicted for age and sex or develop hypoxia (SPO2 < 90%) during a 6-minute walk test (this test can be performed in place of pulmonary function test [PFT] for those unable to perform a reliable PFT due to complex upper airway anatomy)

  21. For participants receiving IL-2 only: evidence of ischemia on cardiac stress test

  22. > 80% stenosis based on carotid doppler ultrasound for patients with NSCLC and HNSCC with > 35 pack year smoking history

  23. Obstructive or restrictive pulmonary disease Note: Post-bronchodilator values: forced expiratory volume (FEV1)/forced vital capacity > 70% or FEV1 > 50% of predicted normal are required for study entry

  24. Suspected pneumonitis or interstitial lung disease (confirmed by radiography or computed tomography [CT])

  25. Treatment on another study with other investigational therapeutic interventional study within 28 days to start of LDC regimen

  26. Known additional malignancy that is active and/or progressive requiring treatment; exceptions including basal cell or squamous cell skin cancer, or other cancer for which the participants has been disease-free for at least 2 years

  27. Psychiatric illness/social situation that would limit compliance with study requirements, as determined by the Investigator

  28. Other severe, acute, or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or that may interfere with the interpretation of the study results, and in the judgement of the Investigator, would the participant inappropriate for the study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Backfill IL-2: Treatment with Lymphodepletion and KSQ-004EX + IL-2

Participants will receive KSQ-004EX and pre-medicated with cyclophosphamide and fludarabine to prevent the lymphodepletion of the chemotherapy.

Given by IV

Given by IV

Given by IV

Given by IV

他の名前:
  • IL-2
実験的:Phase 1 mLDC: Treatment with Modified Lymphodepletion and KSQ-004EX

Participants will receive KSQ-004EX and pre-medicated with cyclophosphamide and fludarabine to prevent the lymphodepletion of the chemotherapy.

Given by IV

Given by IV

Given by IV

実験的:Phase 1/Phase 2: Treatment with Lymphodepletion and KSQ-004EX

Participants will receive KSQ-004EX and pre-medicated with cyclophosphamide and fludarabine to prevent the lymphodepletion of the chemotherapy.

Given by IV

Given by IV

Given by IV

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Safety and adverse events (AEs)
時間枠:Through study completion; an average of 1 year

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Through study completion; an average of 1 year

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Rodabe N Amaria, MD、M.D. Anderson Cancer Center

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年11月21日

一次修了 (推定)

2039年8月1日

研究の完了 (推定)

2041年8月1日

試験登録日

最初に提出

2024年9月13日

QC基準を満たした最初の提出物

2024年9月16日

最初の投稿 (実際)

2024年9月19日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月2日

QC基準を満たした最後の更新が送信されました

2026年10月29日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する